|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
16 December 2017 |
|
Main ID: |
NCT00897923 |
|
Date of registration:
|
09/05/2009 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma
|
|
Scientific title:
|
In Vivo Imaging of Effector Cells in Anti-Lymphoma Therapy |
|
Date of first enrolment:
|
September 2003 |
|
Target sample size:
|
17 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT00897923 |
|
Study type:
|
Observational |
|
Study design:
|
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Gregory Wiseman, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Mayo Clinic |
|
|
Name:
|
Michael M. Graham, PhD, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Holden Comprehensive Cancer Center |
| |
|
Key inclusion & exclusion criteria
|
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed non-Hodgkin's lymphoma
- Indolent or aggressive disease
- Planning to receive a new regimen or starting a regimen of cancer therapy
- At least one tumor lesion measurable in two dimensions as = 1.5 cm by CT scan
PATIENT CHARACTERISTICS:
- ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%
- Life expectancy = 3 months
- No concurrent medical complications that would preclude study compliance
- Not pregnant or nursing
PRIOR CONCURRENT THERAPY:
- At least 3 weeks since prior chemotherapy (except for nonmyelosuppressive treatments)
- At least 3 weeks since prior radiation therapy
- Concurrent rituximab allowed
Age minimum:
18 Years
Age maximum:
120 Years
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Small Intestine Cancer
|
|
Lymphoma
|
|
Intervention(s)
|
|
Radiation: indium In 111-labeled autologous polymorphonuclear leukocytes
|
|
Radiation: indium In 111-labeled autologous peripheral blood mononuclear cells
|
|
Procedure: radionuclide imaging
|
|
Primary Outcome(s)
|
|
Cellular uptake of PBMCs and PMNLs as measured by reader/visual interpretation, semiquantitative grading system, and tumor-to-background uptake ratios
|
|
Number of baseline indium In 111-labeled peripheral blood mononuclear cells (PBMCs) trafficking into tumors
|
|
Number of baseline indium In 111-labeled polymorphonuclear leukocytes (PMNLs) trafficking into tumors
|
|
Number of PBMC and PMNL trafficking prior to vs after therapy
|
|
Secondary ID(s)
|
|
CDR0000529768
|
|
MAYO-IRB-1414-03
|
|
UIHC-LS0383
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|